The conduct of high quality clinical trials is essential to the overall mission ofthe UC Davis Cancer Center. The Clinical Trials Support Unit (CTSU) is a shared resource providing coordination/supervision of clinical research activities, centralized protocol development/implementation, data management, regulatory oversight/review, quality control, and centralized navigation services. CTSU activities are complementary to and integrated with the Protocol Review and Monitoring System (PRMS) described separately in this application.
The Clinical Trials Support Unit provides staff expertise needed to conduct cancer clinical trials, to protect patient safety, maintain the integrity of data collected, respond to regulatory requirements of the University, the National Institutes of Health, trial sponsors, and the Food and Drug Administration, and assure effective communications among the clinical trial team. Thus, it contributes to improved therapies for cancer.
|Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24|
|Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24|
|Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4|
|Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9|
|Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6|
|Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25|
|Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8|
|Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49|
|Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40|
|Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6|
Showing the most recent 10 out of 84 publications